GIP
FATE icon

Granite Investment Partners’s Fate Therapeutics FATE Stock Holding History

Granite Investment Partners’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-17,199
Closed -$280K – 345
2018
Q3 		$280K Buy
+17,199
New +$203K 0.02% 287

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Granite Investment Partners's FATE Position: Q4 2018 in Review

Granite Investment Partners sold out of Fate Therapeutics (FATE) in Q4 2018, closing a stake of 17,199 shares — an estimated $280K sold.

Granite Investment Partners first reported a position in FATE in Q3 2018 and held it in 1 quarter. The position peaked at $280K in Q3 2018. 122 funds tracked by Wall St. Rank hold FATE as of Q4 2018.

  • Granite Investment Partners reported no remaining Fate Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Granite Investment Partners sold 17,199 Fate Therapeutics shares in Q4 2018, an estimated $280K.
  • Granite Investment Partners first reported a position in Fate Therapeutics in Q3 2018 and held it in 1 quarter.
  • Granite Investment Partners's Fate Therapeutics position peaked at $280K in Q3 2018.
  • 122 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2018.

Based on Granite Investment Partners's 13F filing for Q4 2018, filed 13 Feb 2019.